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Abstract
Background: Meta-analysis of randomized controlled trials (RCTs) has been widely conducted for the evaluation of surrogate
endpoints in oncology, but little attention has been given to the adequacy of reporting and interpretation. This review
evaluated the reporting quality of published meta-analyses on surrogacy evaluation and developed recommendations for fu-
ture reporting.
Methods: We searched PubMed through August 2017 to identify studies that evaluated surrogate endpoints using the meta-
analyses of RCTs in oncology. Both individual patient data (IPD) and aggregate data (AD) meta-analyses were included for the
review.
Results: Eighty meta-analyses were identified: 22 used IPD and 58 used AD from multiple RCTs. We observed variability and
reporting deficiencies in both IPD and AD meta-analyses, especially on reporting of trial selection, endpoint definition, study
and patient characteristics for included RCTs, and important statistical methods and results. Based on these findings, we pro-
posed a checklist and recommendations to improve completeness, consistency, and transparency of reports of meta-analytic
surrogacy evaluation. We highlighted key aspects of the design and analysis of surrogate endpoints and presented explana-
tions and rationale why these items should be clearly reported in surrogacy evaluation.
Conclusions: Our reporting of surrogate endpoint evaluation using meta-analyses (ReSEEM) guidelines and recommendations
will improve the quality in reporting and facilitate the interpretation and reproducibility of meta-analytic surrogacy evalua-
tion. Also, they should help promote greater methodological consistency and could also serve as an evaluation tool in the
peer review process for assessing surrogacy research.
Overall survival (OS) is the gold standard primary efficacy end-
point in oncology randomized controlled trials (RCTs), but it of-
ten requires prolonged follow-up and a substantial number of
patients. In addition, evaluation of OS is likely influenced by
subsequent lines of therapies. As such, investigation of surro-
gate endpoints for OS has received increasing interest in
oncology in the recent two decades in the hope of reducing the
duration of trials and decreasing the cost of drug development.
To establish surrogacy, investigators need to provide evidence
that “a drug-induced effect on the surrogate predicts the desired
effect on the clinical outcome of interest” (1,2) using robust sta-
tistical methods before it replaces the definitive endpoint.
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Meta-analysis of RCTs has been widely conducted for the
evaluation of surrogate endpoints in oncology, but little atten-
tion has been given to the adequacy of reporting and interpreta-
tion. The two-stage meta-analytic approach developed by Buyse
et al. requires demonstration of strong correlation between the
surrogate and definitive endpoints (“outcome surrogacy”) as
well as correlation of treatment effects on both endpoints
(“trial-level or effect surrogacy”) (3,4). Meta-analysis of individ-
ual patient data (IPD) remains the optimal approach to meta-
analysis in general, and to surrogacy evaluation in particular,
because it enables the standardization of methods across IPD
sets and robust analysis at both the patient and trial levels
(5). However, because IPD meta-analyses are time and re-
source intensive, meta-analyses of outcome correlation or
trial-level associations using aggregate data (AD) are more
often reported (6).
The PRISMA (7) and PRISMA-IPD (8) statements provide
reporting guidelines for systematic reviews and meta-analyses.
However, some requirements, for example, quantification of
heterogeneity, may not apply to meta-analytic surrogacy evalu-
ation, whereas other important design and analysis aspects
that are unique for surrogacy work are not covered by the
PRISMA or PRISMA-IPD. Therefore, we began by reviewing the
reporting quality of published IPD and AD meta-analyses on
surrogacy evaluation, using the PRISMA and PRISMA-IPD guide-
lines. We also identified the additional items that, if not or in-
completely reported, could severely affect interpretation of
surrogacy studies. We limited this review to the field of oncol-
ogy, in which surrogate endpoints have been frequently investi-
gated. On the basis of our systematic review, we provided
evidence-based recommendations to improve the consistency
and quality of reporting these studies in the future.
Methods
Study Selection and Identification
We conducted a systematic review of published articles that
reported on surrogate endpoint evaluation in oncology using
the meta-analytic approach. Articles were eligible if they evalu-
ated surrogate endpoints using meta-analyses of RCTs in oncol-
ogy and were published in English as full text. Articles were
excluded if surrogacy analyses were based on a single RCT, ob-
served retrospective studies, or single-arm phase I/II studies.
Commentaries, reviews, and studies not focusing on surrogacy
were also excluded. The PubMed database was searched for rel-
evant entries up to August 31, 2017 (with no restriction on the
start date), using the terms: [“surrogate end point” or “surrogate
endpoint” or “surrogate outcome” or “intermediate endpoint” or
“intermediate end point” or “intermediate outcome”] and
[“cancer” or “neoplasms”]. Two authors performed the database
search (W. Xie and M. M. Regan). In addition, reference lists of
relevant review articles were manually searched by a single re-
viewer (W. Xie). Exclusion of ineligible articles after the full text
review was determined by the two reviewers with consensus.
Articles and abstracts were screened in accordance with the
PRISMA guidelines (7).
Data Extraction and Analysis
Articles meeting the eligibility criteria were included for data
abstraction. We collected information regarding the general
characteristics of meta-analyses, study design, and statistical
methods for surrogacy evaluation, reporting of information on
included trials and patient characteristics, and reporting of the
results for surrogacy evaluation. The initial set of items in-
cluded relevant elements for the general meta-analysis from
the PRISMA and PRISMA-IPD as well as particular elements re-
quired for surrogacy evaluation based on the authors’ experi-
ence and pilot review of 10 eligible articles (W. Xie and M. M.
Regan). A few additional items were added during the process
of data extraction from full review and manuscript develop-
ment. The final list comprised those items that, if not or incom-
pletely reported, could severely affect interpretation of the
results from surrogacy analysis. Detailed data elements are
listed in Tables 1 and 2. Data extraction was conducted by a sin-
gle reviewer (W. Xie). Descriptive methods were used for data
summarization and analyses.
Results of the Systematic Review
Characteristics of Eligible Meta-Analysis Studies
Over 900 abstracts were initially identified for screening from
PubMed and review articles. A total of 828 ineligible abstracts
were excluded (non-meta-analysis, methodology papers, re-
view, commentary, or editorial articles, non-English articles;
Figure 1). We conducted the full text review for the 94 poten-
tially eligible articles. Fourteen of 94 articles were excluded
from the review for the following reasons: reanalyzed published
data (n¼ 3 articles), used single-arm trials (n¼ 7), commentary
(n¼ 3), single RCT using countries as analysis units (n¼ 1). The
remaining 80 articles met the inclusion criteria (Figure 1;
Supplementary Table S1, available online).
Notably, the number of meta-analyses on surrogacy evalua-
tion in oncology has grown markedly in recent years, with 60
(75%) of the relevant articles published since 2010 (Figure 2). The
most frequent tumor types examined were colorectal, breast,
and lung cancers (17, 15, and 14 meta-analyses, respectively).
Twenty-two of 80 (27%) meta-analyses used IPD and 58 (73%)
used AD (Table 1). Fifteen (19%) meta-analyses evaluated surro-
gate endpoints in a localized (or locally advanced) disease set-
ting, with disease-free survival (DFS) as the most frequently
evaluated surrogate endpoint (13 of 15, 87%). For metastatic or
advanced diseases (65 studies), progression-free survival (PFS)
or time to progression (TTP) were the major surrogate endpoints
examined (54 of 65, 83%) followed by tumor response (30 of 65,
46%). OS was the definitive endpoint of interest in all but four
studies (Table 1).
Reporting of Surrogacy Evaluation Study Design
Some studies reported a preexisting protocol (7 of 58, 12%; and 7
of 22, 32% in AD and IPD meta-analyses, respectively). For trial
selection, the majority (57 of 58, 98%) of AD meta-analyses
reported using a systematic literature review to identify included
RCTs; 42 (72%) provided a trial selection flowchart. For the 22
meta-analyses using IPD, 15 (68%) reported systematic literature
review and 9 (41%) presented the flowchart (Table 2). The scope
of the reported literature search criteria included study popula-
tion, type of intervention, and other trial characteristics.
Harmonized endpoint definitions across included trials were
more frequently provided in IPD meta-analyses (22 of 22, 100%)
than in AD meta-analyses (23 of 58, 40%). Meanwhile, heteroge-
neity in defining the endpoints across included trials was
reported in 41 studies: nine (41%) in IPD and 32 (55%) in AD
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meta-analyses. The reported variations in endpoint definitions
included type of failure events for DFS or PFS endpoints, disease
evaluation criteria (eg, World Health Organization [WHO] vs
Response Evaluation Criteria in Solid Tumors [RECIST]), end-
point assessment schedule, and censoring rules for time-to-
event endpoints (Table 2).
In terms of the surrogacy criteria, 19 (24%) meta-analyses
predefined the rule for declaring surrogacy, of which 11 meta-
analyses specified an R-squared of 0.7 or higher as the cut point
to determine a statistically acceptable correlation.
Reporting of Included Trial and Patient Characteristics
Among the AD meta-analyses, 13 of 58 (22%) reported years of
enrollment for included RCTs, and reporting of this variable was
17 of 22 (77%) for IPD meta-analyses. Patients’ ages, disease
stages or characteristics, trial follow-up duration, and numbers
of events (for time-to-event endpoints) from included trials
were also more frequently reported in IPD meta-analyses than
in AD meta-analyses (Table 2).
Reporting of Outcome Surrogacy
Fifty studies (63%) reported outcome surrogacy (ie, correlation
between the surrogate and definitive endpoints irrespective of
treatment effect). Fourteen IPD-based studies reported using a
copula model to estimate individual-level correlation coefficient
for failure-time endpoints. Copula is a modeling analysis that
describes the dependence of two endpoints through modeling
their distributions jointly. There are a series of candidate mod-
els (eg, Clayton’s, Hougaard’s, and Plackett’s models) for time-
to-event endpoints (9); hence, application of the copula method-
ology consists of selecting an appropriate copula model from
among these candidates. Although nine (64%) studies specified
the type of copula, only three studies clearly stated the method
(eg, based on the Akaike information criteron) used to select a
copula model. Correlation was expressed through the
Spearman or Kendall’s tau correlation coefficients in 12 (86%)
studies, but without explicit justification for the choice of mea-
sure (Table 2; Supplementary Table S2, available online). Nine
IPD meta-analyses also analyzed a binary surrogate (eg, tumor
response), whose correlation with OS was quantified as hazard
ratios from Cox’s regression model, log-rank test of statistical
significance, or survival odds ratios from a joint copula.
Outcome surrogacy was also reported using AD, which ex-
amined the correlation between endpoints on estimated sum-
mary metrics (such as median time to event, event rate at
selected timepoints, or response rate) with trial and treatment
arm as the analysis unit. Twenty-nine studies reported use of a
correlation coefficient to measure the strength of correlation,
including two studies using aggregated IPD. Although the ma-
jority of studies explicitly specified the type of correlation coef-
ficients (Pearson, Spearman, or Kendall’s tau) or whether
weights were used in the calculation, only about 50% studies
provided confidence intervals for these estimates. The coeffi-
cient of determination (ie, R-squared) from a linear regression
(unweighted, weighted, or error-in-variable adjusted; Table 2)
was reported in 20 studies, but the R-squared confidence inter-
val and the regression equation were not fully reported (5 of 20,
25%; and 9 of 20, 45%, respectively).
Reporting of Trial-Level Surrogacy
Seventy-four studies reported trial-level surrogacy by examin-
ing correlation between the treatment effect on the surrogate
endpoint and the treatment effect on the definitive endpoint.
The majority of meta-analyses (71 of 74, 96%) reported using
trial as the analysis unit, whereas three IPD-based studies
reported using country or center as the analysis unit. Treatment
effect was measured in a variety of ways, including absolute dif-
ference in medians of DFS or PFS, or response rates; ratios or
percent increases in medians of DFS or PFS, or response rates;
and hazard ratios of DFS or PFS, or odds ratios of response (with
or without log transformation). Trial-level correlation was
quantified as a correlation coefficient (Spearman or Pearson) in
37 studies, with confidence interval reported in about 50% of
studies. Fifty-four studies reported R-squared from a linear re-
gression; the types of regression included unweighted,
weighted, or error-in-variable adjusted (Table 2). For 12 studies
that reported copula R-squared, introduced by Burzykowski
et al. (9), five studies used error-adjusted models. In addition,
incomplete reporting on R-squared confidence interval or re-
gression equation was noted in both conventional or copula
model based regression analyses (Table 2). Other novel trial-
level correlation measures, such as the Bayesian adjusted R-
squared proposed by Renfro (10), were not reported in the meta-
analyses that were reviewed.
Table 1. Characteristics of 80 meta-analysis study articles reviewed
(up to August 31, 2017)
Characteristic No. (%)








Disease stage and surrogate endpoints*
Localized or locally advanced 15 (19)




Metastatic or advanced† 65 (81)
Tumor response 30 (46)




OS and DFS or EFS or PFS 7 (9)
PFS 1 (1)
PPS 3 (4)
No. of trials included, median (range) 24 3–191
No. of patients in the included trials 9223 870–67158
*Total is greater than 100% because some studies examined multiple diseases or
multiple endpoints. AD ¼ aggregate data; DFS ¼ disease-free survival; EFS ¼
event-free survival; IPD ¼ individual patient data; MFS ¼ metastasis-free sur-
vival; OS ¼ overall survival; PFS ¼ progression-free survival; PPS ¼ postprogres-
sion survival; TTP ¼ time to progression.
†Included four hematologic cancers, which evaluated PFS or response as surro-
gates for OS.
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Reported elements No. (%) No. (%)
Reporting of surrogacy evaluation study design (n¼80) 58 22
A protocol existed for the meta-analysis 7 (12) 7 (32)
Systematic search 57 (98) 15 (68)
Specified search term(s) 55 (95) 8 (36)
Trial selection flowchart 42 (72) 9 (41)
Harmonized endpoint definition 23 (40) 22 (100)
Variation in endpoint definition across trials 32 (55) 9 (41)
Variation in time-to-event endpoint failuretypes 20 (34) 1 (5)
Variation in endpoint evaluation criteria 8 (14) 4 (18)
Variation in endpoint assessment schedule 4 (7) 3 (14)
Variation in censoring rules 0 (0) 1 (5)
Specified surrogacy criteria (eg, correlation cutoff) 13 (22) 6 (27)
Reporting of included trial and patient characteristics (n¼80) 58 22
Patient enrollment period 13 (22) 17 (77)
Patient age 14 (24) 14 (64)
Patient disease characteristics 25 (43) 17 (77)
Number of events 4 (7) 11 (50)
Median follow-up duration 19 (33) 19 (86)
Reporting of outcome surrogacy (using IPD)
Reporting of correlation between time-to-event endpoints using a copula (n¼14) n/a 14
Copula type n/a 9 (64)
Copula selection criteria n/a 3 (21)
Type of correlation coefficient n/a 12 (86)
Confidence interval for correlation n/a 13 (93)
Reporting of correlation between binary surrogates and time-to-event endpoint (n¼9) n/a 9
Type of correlation measure
Hazard ratio from Cox regression n/a 3 (33)
Hazard ratio from Bayesian hierarchicalanalysis n/a 1 (11)
Log-rank test of significance n/a 1 (11)
Survival odds ratio from Plackett copula n/a 4 (44)
Reporting of outcome surrogacy (using trial level summary data)
Reporting of correlation between endpoints (n¼29) 27 2
Type of correlation coefficient
Non-parametric (Kendall’s tau andSpearman) 15 (56) 2 (100)
Pearson (8 weighted, 1 unweighted) 9 (33) 0 (0)
Not reported 3 (11) 0 (0)
Confidence interval for correlation 15 (56) 1 (50)
Reporting of R-squared from linear regression (n¼20) 17 3
Type of linear regression specified
Weighted by sample size 14 (82) 2 (67)
Weighted by inverse variance of surrogate 0 (0) 1 (33)
Error-in-variables adjusted 1 (6) 0 (0)
Unweighted simple linear regression 2 (12) 0 (0)
R-squared confidence interval 3 (18) 2 (67)
Regression equation 8 (47) 1 (33)
Bubble plot for regression model 14 (82) 3 (100)
Reporting of trial-level surrogacy
Reporting of correlation of treatment effects on endpoints (n¼37) 33 4
Type of correlation coefficient specified
Pearson (11 weighted, 1 unweighted) 10 (30) 2 (50)
Spearman 20 (61) 2 (50)
AUC 1 (3) 0 (0)
Not reported 2 (6) 0 (0)
Confidence interval for correlation 15 (45) 2 (50)
(continued)
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Surrogate threshold effect (STE), the minimum treatment
effect on the surrogate necessary to predict a non-zero effect
on the definitive endpoint, is another metric to evaluate trial-
level surrogacy (11). To obtain the STE, Burzykowski and Buyse
proposed using the 95% prediction limits of the regression line
for the trial-level surrogacy (11). For the meta-analysis studies
we reviewed, 26% (21 of 80) reported STE: 15 studies reported
using the 95% prediction limits of the regression line, three
studies reported using the 95% confidence interval, and three







Reported elements No. (%) No. (%)
Reporting of R-squared from linear regression of treatment effects on endpoints (n¼54) 38 16
Type of linear regression specified
Weighted by sample size 24 (63) 14 (88)
Weighted by other factors 4 (11) 1 (6)
Unweighted simple linear regression 4 (11) 0 (0)
Errors-in-variables adjusted 3 (8) 0 (0)
Not reported 3 (8) 1 (6)
R-squared confidence interval 12 (32) 14 (88)
Regression equation 32 (84) 6 (38)
Bubble plot for regression model 32 (84) 16 (100)
Reporting of R-squared from a copula model (n¼12) n/a 12
Type of regression specified
Errors-in-variables adjusted n/a 5 (42)
Weighted by sample size n/a 1 (8)
Not reported n/a 6 (50)
R-squared confidence interval n/a 11 (92)
Regression equation n/a 6 (50)
Bubble plot for regression model n/a 12 (100)
Reporting of STE (n¼21) 9 12
STE estimation method
Using regression line prediction interval 5 (56) 10 (83)
Using regression line confidence interval 3 (33) 0 (0)
Method not specified 1 (11) 2 (17)
Reporting of additional analysis (n¼80) 58 22
Any sensitivity analysis 20 (34) 11 (50)
Any subgroup analysis 40 (69) 11 (50)
Any cross-validation analysis (eg, leave-one-out) 4 (7) 10 (45)
Any external validation analysis (eg, using other trials) 5 (23)
*AD¼aggregate data; AUC¼area under the curve; IPD¼individual patient data; n/a ¼not applicable; STE¼surrogate threshold effect
922 abstracts screened from 
PubMed and Review arcles
94 full text arcles assessed 
for eligibility
80 eligible studies included 
in the analysis







Level II Screening 
(14 excluded)
Re-analyzed published data (3)
Used single-arm trials (7)
Commentary (3)
Single RCT using country as units (1)
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Figure 2. Publication trends for meta-analytic surrogacy evaluation in oncology.
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Reporting Sensitivity, Subgroup, and Validation
Analyses
Overall, 31 studies (39%) reported additional sensitivity analysis,
such as use of various cutoffs for follow-up times, exclusion of
certain trials, use of alternative endpoint definitions, use of al-
ternative weights, or statistical models for analysis. A total of 51
(64%) studies reported subgroup analyses. The most commonly
reported subgroup analyses were by type of treatment (40, 50%),
by enrollment or publication years (18, 23%), and by patient
characteristics (16, 20%). Eighteen studies also reported valida-
tion analysis and the majority used a leave-one-out validation
(Table 2; Supplementary Table S3, available online).
Recommendations for the Future
Our systematic review identified wide variability and reporting
deficiencies in the published meta-analyses on surrogate end-
point evaluation in oncology. To assist in the comprehensive
and consistent reporting of meta-analytic surrogacy evaluation,
we propose a checklist and recommendations (Table 3). Some
design aspects are covered by the standard PRISMA (7) and
PRISMA-IPD (8) guidelines (eg, items 5–13 on reporting of meth-
ods for study design and data collection). Other aspects are
more specific and essential for surrogacy evaluation (such as
items 14–16 on reporting of surrogacy criteria and analysis
methods). We highlight below the key aspects of the design and
analysis of surrogate endpoints and why they should be clearly
reported in meta-analysis studies.
Develop Protocol for Surrogacy Evaluation
The PRISMA and PRIMA-IPD guidelines recommend registration
and reporting of the protocol of any systematic review and
meta-analysis. Compared with other meta-analyses aiming for
the pooled treatment effects, meta-analysis for surrogacy evalu-
ation usually targets broader treatment classes, more mixed
study population, and multiple surrogate candidates. With the
heterogeneity of trials and rich analyses of multi-level data
(outcome level vs trial level), there is a greater risk of post-hoc,
data-driven decision-making. The development and adherence
to a protocol is therefore critical for meta-analytic surrogacy
analyses.
A protocol will help investigators to choose appropriate can-
didate surrogates, generate hypotheses in the context of dis-
ease, and define a priori the threshold of correlation deemed
necessary to meet the surrogacy criteria. As noted above, an R-
squared of 0.7 or above has been the conventional degree of cor-
relation used to define surrogacy in oncology. However, it
should be realized that different types of surrogates (eg, clinical
or biomarker based) may serve different roles in different
phases of drug development (12). In one instance, a RCT may be
designed using an intermediate clinical endpoint as a strong
surrogate for OS to reduce trial duration and sample size. In
other situations, lack of improvement of a very early endpoint,
such as biochemical recurrence before radiographic recurrence
of a prostate cancer, can be used to screen for ineffective drugs
in an early-phase clinical trial, even though presence of a bio-
chemical recurrence may not have a strong correlation with OS.
Hence, the threshold of success needs to be defined in a con-
text-dependent manner as well as ideally tied to a specific
purpose.
The rigorously planned protocol should include meta-
analysis study design, trial and patient selection, endpoint defi-
nition, and a statistical analysis plan that precisely defines
upfront all details of the surrogacy analysis method that will be
conducted, including, for example, the details method used to
choose a model over another. It is best to define subgroup and
sensitivity analyses as a priori in the protocol and to justify
them in the context of disease. A well-developed protocol will
help investigators in projecting the timeline, estimating the
cost to conduct these analyses, and avoiding post-hoc data in-
terrogation for the designed results. To increase transparency,
the protocol should be explicitly reported in the meta-analyses
of surrogate evaluation and made publicly accessible. Notably,
several meta-analyses that we reviewed published their proto-
cols (13,14), setting good examples of using well-developed pro-
tocols to guide analysis for surrogacy evaluation.
Sufficient Reporting on Trial Selection
In practice, very few meta-analyses were able to include all po-
tentially eligible trials for surrogacy evaluation. A recent review
article has indicated that only a subset (about 50%) of potential
eligible studies were ultimately included in even the most rigor-
ous meta-analyses for trial-level surrogacy evaluation (15).
Besides the common trial selection issues in meta-analyses (eg,
use of only published articles, resource limitation, data sharing
obstacles for IPD collection), surrogacy evaluation requires out-
come and treatment effect data for multiple endpoints, and not
all eligible trials can provide such complete data needed for sur-
rogacy evaluation. For instance, some AD meta-analyses can in-
clude only RCTs that reported both PFS and OS hazard ratios
(16). The excluded trials that did not report PFS and OS hazard
ratios were more likely to have negative treatment effects on
these endpoints (17,18).
Whereas for other meta-analyses publication bias usually
leads to exaggerated treatment effects, surrogacy evaluation
may encounter other challenging issues. A simulation study
demonstrated that surrogacy estimation via regression models
is more accurate and precise in the settings of a larger number
of trials, a low rate of censoring, and a wide range of treatment
effects (ie, including both positive and negative trials) (19).
When one or more factors deviate from the “optimal” scenarios,
regression tends to underestimate the definitive surrogacy with
increased variability (19). A wide range of treatment effects
across included trials improves the performance of the regres-
sion model and the magnitude of R-squared, because the vari-
ance of the regression coefficient is inversely proportional to
the spread of the predictor variable. Hence, heterogeneity of
treatment effects (ie, including both positive and negative trials)
is an advantage rather than a drawback in a meta-analysis
aimed at surrogate validation.
Use of nonexhaustive sets of trials might be less of a concern
compared with other meta-analyses as long as the included tri-
als reflect the expected range of heterogeneity of treatment
effects. However, it is still important for the study selection pro-
cess to be inclusive and explicit for a rigorous surrogate evalua-
tion. To reduce potential bias due to trial selection, reasons for
trial exclusion should be reported at the trial selection stage. A
comparison of trial characteristics and range of treatment
effects across trials between included and excluded eligible tri-
als can also provide valuable information for trial representa-
tion and generalization.
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Table 3. Recommendation for ReSEEM
Section and topic No. Checklist items
Title
Title 1 Identify whether this is a report of meta-analysis of individual patient or AD; specify
surrogates examined in the context of disease (eg, PFS as a surrogate endpoint for OS
in advanced lung cancer: meta-analyses of IPD)
Abstract
Structured summary 2 Provide a structured summary including as applicable:
• Background: state main objectives, surrogate endpoints and definitive endpoint ex-
amined, participants and interventions
• Methods: report eligibility criteria, data sources (individual patient or AD), surrogacy
criteria, and primary analysis method for surrogacy evaluation
• Results: provide key results for patient-level (or outcome level) and trial-level surro-
gacy analysis
• Conclusion: summarize the strength of surrogacy and implications for future
research
Introduction
Rationale 3 Provide justification for the use of a surrogate endpoint in the context of disease
Objectives 4 State the objective of meta-analysis or any prespecified hypotheses for surrogacy evalu-
ation, including endpoints examined, participants, interventions, and study design
Methods
Design/data collection
Protocol and registration 5 Follow PRISMA and PRISMA-IPD statement
Provide rationale for choice of endpoint, treatment, and population; generate hypothe-
ses in a context-dependent manner; include details on study design, trial, and patient
selection, endpoint definition, and a statistical analysis plan
Eligibility criteria 6 Follow PRISMA and PRISMA-IPD statement
Information sources 7 Follow PRISMA and PRISMA-IPD statement
Search 8 Follow PRISMA and PRISMA-IPD statement
Study selection 9 Follow PRISMA and PRISMA-IPD statement
Data collection process 10 Follow PRISMA and PRISMA-IPD statement
Data items 11 Follow PRISMA and PRISMA-IPD statement
Risk of bias within studies 12 Follow PRISMA and PRISMA-IPD statement
Risk of bias across studies 13 Follow PRISMA and PRISMA-IPD statement
Endpoint definitions 14 Precisely define all endpoints examined
Provide description of between-trial variability in endpoint definition (eg, disease as-
sessment criteria and schedule, type of events included in time to event endpoint,
methods used for censoring endpoints)
Surrogacy criteria 15 Define surrogacy criteria and cutpoint determination in the specific context of disease;
provide justification for what level of correlation would be deemed as surrogacy at in-
dividual and trial level
Statistical analyses 16
Individual-level correlation A Specify copula methods used to estimate individual-level correlation: choice of cop-
ula and justification, choice of correlation coefficient (eg, Spearman vs Kendall’s
tau), and rationale for the choice
Specify other methods used for individual-level correlation if appropriate (eg, hazard
ratio from Cox regression, landmark or time-dependent model, information the-
ory, Bayesian methods)
Outcome correlation using aggregate data B Specify the analysis unit (eg, trial, arm, country, and center)
Specify type of outcome measures (eg, response rate, median time to event, event
rate at selected timepoints, and rationale for timepoint selection)
Specify how outcome measure is estimated for each study (eg, from Kaplan-Meier
methodology or cumulative incidence function for time to event endpoints; from
trial reported or extracted from Kaplan-Meier curves)
State the statistical model to calculate correlation coefficient or R-squared (eg,
weighted linear regression, error in variable regression, or nonparametric model;
choice of weights and rationale)
Trial-level correlation C Specify the analysis unit (eg, trial, country, and center)
Specify the metrics for treatment effects (eg, hazard or odds ratio, whether loga-
rithm transformation is used)
Specify how treatment effect is estimated for each study (eg, use of Weibull or Cox
regression, from marginal or joint copula model, from trial-reported or imputed)
(continued)
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Sufficient Reporting of Characteristics of the Included
RCTs
It is important to report on all trials and patient characteris-
tics for the included trials (eg, class of therapy, enrollment
period, follow-up duration, patient characteristics). Patient
characteristics, such as age and tumor staging, are important
prognostic factors with respect to disease evolution and po-
tentially affect treatment options, TTP, postprogression sur-
vival, comorbidity, and cause of death. Surrogacy results can
be appropriately interpreted only if the study population is
well characterized.
Furthermore, in meta-analysis for surrogacy evaluation,
broad trial entry criteria increase the degree of heterogeneity
between trials. However, it is possible that the strength of surro-
gacy may vary according to certain trial-level or patient charac-
teristics. Analysis by subgroups is an important strategy to
explore heterogeneity. Moreover, with the emergence of check-
point inhibitor-based immunotherapy, we have seen that al-
though most patients do not benefit, a clinically relevant
minority have major benefit. Similarly, some targeted therapies
may have greater benefit in a selected population subset with a
mutated gene. Sufficient reporting of trial and patient charac-
teristics provides supporting evidence and justification for the
planned subgroup and sensitivity analyses.
In addition, for time-to-event endpoints, such as DFS and
PFS, follow-up duration and numbers of events determine the
precision of point and interval estimates. Collection and report-
ing of such information help investigators choose appropriate
weights for the weighted regression analysis in the presence of
unbalanced follow-up across trials. Unfortunately, in most stud-
ies we reviewed, authors only reported sample sizes of included
RCTs and performed linear regression weighted on trial sample
size without considering study follow-up duration.
Table 3. (continued)
Section and topic No. Checklist items
State the statistical model to calculate correlation coefficient or R-squared (eg,
weighted linear regression, error in variable regression, or nonparametric model;
choice of weights and rationale)
Specify the statistical method used to calculate STE (eg, type of regression, how pre-
diction interval is constructed)
Validation D Specify statistical methods used to validate surrogate evaluation (eg, leave-one-out
across validation, bootstrap validation, and external validation)
Sensitivity and subgroup analysis E State type of sensitivity and subgroup analysis
Provide justification for these additional analyses in the context of disease
Results
Study selection 17 Follow PRISMA and PRISMA-IPD statement
Risk of bias within studies 18 Follow PRISMA and PRISMA-IPD statement
Risk of bias across studies 19 Follow PRISMA and PRISMA-IPD statement
Study characteristics 20 Summarize trial and patient characteristics for each included trial (eg, sample size,
phase, interventions, disease stage, years of enrollment, follow-up period) and pro-
vide the citations
Provide comparison of trial characteristics between included and excluded eligible trials
Endpoints summary 21 Provide summary statistics for endpoints examined (eg, number of events, median time
to events, event free rate at selected timepoints, response rate), by trial and treatment
arm
Provide trial-specific hazard/odds ratio estimates (or other metrics for treatment effect
if appropriate) and confidence intervals for each endpoint; a table or forest plot is
recommended
Surrogacy analysis 22 Present results of each type of surrogacy analysis done, including number of patients
and number of trials (or units), any exclusion from analysis, confidence interval for
correlation coefficient or R-squared, regression equation if appropriate
Provide bubble plot of regression model, with regression line and prediction interval
Present STE in the context of disease and implication for the trial design
Validation 23 Present results from validation analyses; indicate any discrepancy between main and
validation findings
Additional analysis 24 Follow PRISMA and PRISMA-IPD statement
Conclusion
Summary of evidence 25 Summarize the strength of surrogacy in the context of prespecified hypothesis, includ-
ing subjects, interventions, and trial characteristics
Interpret results in the context of other evidence; consider its relevance, generalization,
and implication for future trial design
Limitations 26 Discuss limitations at various levels (eg, risk of bias, incomplete trial inclusion, variation
in endpoint definition, incomplete data, reporting bias)
Conclusions 27 Summarize the strength of surrogacy and implications for future research.
Funding
Funding 28 Follow PRISMA and PRISMA-IPD statement
*AD ¼ aggregate data; IPD ¼ individual patient data; PFS ¼ progression free survival; OS ¼ overall survival; ReSEEM ¼ reporting of surrogate endpoint evaluation using
meta-analyses; STE ¼ surrogate threshold effect.
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Adequately Define Endpoints for Surrogacy Evaluation
For IPD meta-analyses, it is important to define endpoints ac-
curately, with details on trial-specific disease assessment crite-
ria and schedule, because they are integral parts of endpoint
definitions. For AD meta-analyses using the protocol defini-
tion, efforts need to be made to assess and report variability in
definition of endpoint. Thorough and transparent reporting
does not solve issues of inconsistent endpoint definition from
trials’ initial designs, but it could highlight the potential prob-
lems that need to be considered in interpretation of results. For
example, Colloca and Venturino (20) reported how heteroge-
neous criteria (WHO and RECIST) and wide ranges of timing
(between 6 and 24 weeks) of assessments affect response and
PFS rate estimation in first-line chemotherapy trials for ad-
vanced ovarian cancer. Several meta-analyses reported com-
bining TTP and PFS as the same endpoint because of
inconsistent endpoint definitions across the included trials
and performed additional subgroup and sensitivity analyses to
assure robust results (21,22). The Intermediate Clinical
Endpoints in Cancer of the Prostate (ICECaP) Working Group
identified important variations in local recurrence determina-
tion and in radiographic assessment methods for DFS and MFS
endpoints in trials for localized prostate cancer (23). A subcom-
mittee has been formed with the goal of harmonizing end-
points and data collection in future trials and to address
incorporation of novel imaging within them. Incorporation of
standardized endpoints for disease evaluation is also an im-
portant consideration for future trial designs, as has been
attempted for adjuvant breast cancer studies (24) and for vari-
ous diseases by the DATECAN group in Europe (25–28).
Comprehensive Reporting of Surrogacy Analysis
Methods and Results
Surrogacy evaluations are subject to numerous statistical deci-
sions. Inconsistent and incomplete reporting of the analysis
methods and results leads to difficulty in assessing the appro-
priateness of the analyses and interpretability of study findings.
For example, in the reporting of copula model-based individual-
level and trial-level correlation, the choice of a copula (eg,
Clayton’s, Hougaard’s, or Plackett’s model) or a correlation coef-
ficient (Spearman’s rho vs Kendall’s tau) needs to be transpar-
ent. It is possible that applying different copula models to the
same dataset can lead to different conclusions about the nature
and strength of association of two endpoints. Hence selecting
an appropriate copula based on the goodness-of-fit (eg,
goodness-of-fit tests, Akaike information criterion) (9,29,30) has
been recommended to avoid post-hoc selection based on
results. Empirically, we have noted Spearman’s rho tended to
be larger than Kendall’s tau, and thus the choice of a measure
of correlation is important in considering results of a study
within the context of others. For studies that correlate DFS or
PFS rates with OS rates at specific timepoints, it is important to
justify the timepoint selection in the context of disease. The
confidence intervals for the point estimate of R-squared as well
as regression coefficients are essential in the reporting of trial-
level correlation using linear regression. We also recommend
reporting of prediction intervals (rather than confidence inter-
vals) of regression line for the STE analysis because the interest
is to predict the treatment effect on the definitive endpoint
based on the observed treatment effect on the surrogate end-
point. In addition, surrogacy evaluation via regression analysis
is sensitive to outliers, influential points, or nonlinear associa-
tions. The Anscombe’s quartet (31) demonstrates the impor-
tance of graphing data (such as bubble plots and residual plots)
along with providing numerical statistical metrics for surrogacy
evaluation.
Validation and Sensitivity Analysis
It is also essential to validate a surrogacy model using well-
established methods. The best situation is when trials not in-
cluded in the meta-analysis can be used to validate the results
of the surrogacy analyses, for instance, when IPD could be col-
lected from a subset of trials and AD from the other trials (32).
The leave-one-out cross-validation is also a commonly used ap-
proach when external datasets are limited. Validation assesses
the prediction accuracy of a surrogate model. It is also an im-
portant tool to identify a potential influential outlier that greatly
affects the slope of the regression line. Unfortunately, very few
AD meta-analyses we reviewed reported validation for their
surrogacy models.
For surrogacy evaluation, sensitivity and subgroup analysis
provide further reassurance that the results are robust. For ex-
ample, in the assessment of time to metastasis as a surrogate
for prostate cancer-specific survival, a large proportion of these
endpoints was censored due to non-prostate cancer deaths. As
such, the ICECaP study team performed a sensitivity analysis by
using cumulative incidence estimates of endpoints and subdis-
tribution treatment effect hazard ratio estimates from compet-
ing risk models (23).
Discussion
Based on the systematic review of the reporting of the 80 meta-
analyses, the conduct and reporting of surrogacy evaluation is
inadequate. We have proposed a set of guidelines to improve
the quality of the reporting of surrogate endpoint evaluation us-
ing meta-analyses (ReSEEM; Table 3), which can be used along-
side the existing PRISMA and PRISMA-IPD guidelines for
reporting meta-analyses.
The proposed guidelines apply to both IPD and AD meta-
analytic surrogacy evaluation in general. Both types of surro-
gacy evaluation require adequate reporting to provide valuable
information. When possible, IPD meta-analyses are preferred.
As previously mentioned (5,6,33), the availability of IPD allows
harmonizing the endpoint, estimating patient-level correlation,
applying the copula model-based approach for trial-level corre-
lation, and conducting more comprehensive subgroup and
sensitivity analyses. Hence, formal surrogate evaluation should
be based on a rigorous IPD meta-analysis at both the patient
and trial levels. However, as a more expeditious approach, AD
meta-analyses may provide some preliminary evidence before
a more thorough but resource-intensive IPD meta-analysis is
conducted. It can also serve for validation purposes if a
plausible surrogate has been confirmed from a subset of trials
with IPD.
The main focus of our review was to assess the quality of
reporting of surrogate evaluation. Several previous studies ex-
amined the strength of surrogacy, suggesting that the relation-
ship of DFS and PFS with OS vary considerably across tumor
types (15,33–35). The challenges of identifying a valid surrogate
for OS in cancer RCTs were attributed to multifaceted technical
and clinical issues, such as the use of nonexhaustive sets of tri-
als, RCTs allowing crossover after progression, and effective
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salvage or subsequent lines of therapies (33,35). A recent simu-
lation study by Broglio and Berry (36) showed that correlation
between PFS and OS hazard ratios weakens as the median post-
progression survival increases. Therefore, effective subsequent
treatment may dilute the PFS and OS association. These studies
provided important insights on the proper interpretation of sur-
rogacy evidence in the context of the disease, treatment, trial
designs, and chronological time.
In line with previous studies (6,33), our review revealed the
heterogeneity of statistical methods for surrogacy evaluation,
further highlighting the importance of building consensus on
appropriate statistical techniques for surrogacy evaluation. Shi
et al. (19) made head-to-head comparisons of several trial-level
surrogacy measures in a large-scale simulation-based study,
but no optimal approach was recommended. The authors, how-
ever, identified important trial characteristics that most af-
fected the performance of these metrics and made practical
recommendations for real applications (19). Efforts are also un-
derway to develop sophisticated and integrated software for
surrogacy evaluation (4,37). In the absence of uniformly ac-
cepted methods for surrogacy evaluation, we advocate trans-
parency in the reporting of statistical decisions.
Notably, the contemporary meta-analytic surrogacy evalua-
tion mainly focuses on radiographically based clinical end-
points such as DFS, PFS, and tumor response in the context of
chemo- and targeted-therapies (Supplementary Table S1, avail-
able online). In the new era of immuno-oncology, reevaluation
of the surrogacy of these endpoints is warranted. The surrogacy
of novel endpoints in immune-oncology, such as immune-
related response and correlative immune endpoints, also needs
investigation (38). Moreover, there may be a difference in dis-
ease setting such as progression metastatic disease in meta-
static disease vs progression to metastatic disease in the
adjuvant or curative setting. Molecular, genetic, or immuno-
profiling markers have great potential for use in clinical oncol-
ogy, but few biomarkers have been robustly validated or
confirmed as the surrogate for clinical endpoints through meta-
analytic approach. The “outcome surrogacy” can be easily dem-
onstrated by proving a biomarker’s prognostic value through
individual studies; however, there are greater challenges to
demonstrate trial-level surrogacy because the latter requires
high-quality biologic samples and standardized assays across
multiple trials (39,40). With the increasing interest in exploring
surrogate biomarkers, we expect formal validation of bio-
markers through a robust meta-analytic approach will evolve in
the future. The current reporting guidelines can be extended in
the future to address additional aspects from the meta-analysis
of a surrogate biomarker.
Meta-analysis of RCTs is a widely used approach for surro-
gacy evaluation in oncology. Our ReSEEM guidelines and rec-
ommendations will improve the quality in reporting and
facilitate the interpretation and reproducibility of meta-
analytics surrogacy evaluation. In an era with emerging novel
therapies and enhanced understanding of cancer biology and
genetics, identification of novel, more rapid clinical endpoints
are critically needed to expedite drug development and to de-
rive benefit for subpopulations for a personalized medicine.
Given the rapid growth in this area, our ReSEEM guidelines
should help promote greater methodological consistency and
could also serve as an evaluation tool in the peer review pro-
cess for assessing surrogacy research. These recommenda-
tions have high potential to foster more efficient trial design
and conduct in the future.
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